



## OWNING POTENTIAL

### Transcript:

#### Mark Flanagan

What makes Xeljanz different is the fact that it's a small molecule and it can be dosed orally. It's the first in a class of compounds called JAK inhibitors and the Janus kinase program or JAK program really started at Pfizer. My name is Mark Flanagan I'm an associate research fellow at Pfizer. Once the exploratory biology was done and we had a lead molecule to work with I worked with my colleagues to synthesize approximately a thousand synthetic analogs of that original lead until we eventually found Tofacitinib which we call today Xeljanz. The molecule that we found looked very very promising. It is very gratifying to see something that we worked on in all those years of research now translated into a new treatment option for patients. We found a drug that can potentially help make them feel better that's really an exciting moment for for us. I think that this this program is really an example of people people owning it. People working hard doing their job, working together collaboratively, so this is really a Pfizer story from beginning to end and something that the organization I think is very proud of. It's a great feeling.